
Perry Baromedical
Multiplace Series
$150,000 - $400,000+
Military-funded research, Israeli Defense Forces studies, and what the evidence says about HBOT for post-traumatic stress.
Key Takeaways
Post-traumatic stress disorder affects approximately 6% of the US population at some point in their lives, with significantly higher rates among military veterans (11–20% of Iraq and Afghanistan veterans). Standard treatments — cognitive behavioral therapy, EMDR, and medication (SSRIs) — leave approximately 30–40% of patients with residual symptoms. This treatment gap has driven interest in HBOT as an adjunct therapy, particularly in military medicine where PTSD often co-occurs with traumatic brain injury from blast exposure.
The connection between HBOT and PTSD is partly explained by the overlap with TBI — many veterans with PTSD also have blast-induced brain injuries that contribute to symptom severity. HBOT reduces neuroinflammation in brain regions associated with PTSD (amygdala, hippocampus, prefrontal cortex), improves cerebral blood flow to areas involved in emotional regulation and memory processing, and may promote neuroplasticity in trauma-affected neural circuits. Some researchers propose that HBOT helps create a "neurological foundation" that makes traditional PTSD therapies more effective by restoring function to brain regions that were previously too damaged or inflamed to respond to talk therapy.
Recommended Protocol
Pressure
1.5–2.0 ATA
Sessions
40–60 sessions
Duration
60 minutes per session
Multiple studies have examined HBOT for PTSD, primarily in military populations. Harch et al. (2012) showed significant improvement in PTSD symptoms alongside cognitive improvements in veterans with blast-induced mTBI treated at 1.5 ATA. Doenyas-Barak et al. (2022) demonstrated improvement in treatment-resistant PTSD symptoms in Israeli veterans after HBOT at 2.0 ATA, with improvements in brain activity on functional MRI. The US Department of Defense has funded several HBOT-PTSD studies. However, separating the PTSD benefit from the TBI benefit remains challenging since the conditions frequently co-occur. The evidence is moderate and growing, particularly for PTSD with comorbid TBI.
Off-Label Use
PTSD is not an FDA-approved indication for HBOT. Treatment is considered off-label and is typically not covered by insurance. Consult your physician before starting any HBOT protocol.
Based on the protocol requirements — minimum 1.5 ATA, Clinical Grade or Advanced Wellness tier. Sorted by clinical credibility score.

Perry Baromedical
$150,000 - $400,000+

Perry Baromedical
$50,000 - $90,000

Perry Baromedical
$55,000 - $95,000

Perry Baromedical
$65,000 - $110,000

Perry Baromedical
$100,000 - $160,000

Perry Baromedical
$80,000 - $130,000
The VA has funded multiple HBOT-PTSD research studies and some VA facilities offer HBOT on a case-by-case basis, but it is not a standard VA treatment for PTSD. Coverage depends on the specific VA facility and whether the veteran qualifies for a research protocol. Several veteran advocacy organizations are pushing for broader VA adoption.
No. HBOT should be considered an adjunct to, not a replacement for, evidence-based PTSD treatments like CBT, EMDR, and medication. The most promising approach appears to be combining HBOT with traditional therapy — the neurological improvements from HBOT may make patients more responsive to psychological interventions.
The protocols are very similar because PTSD and TBI frequently co-occur and share neuroinflammatory mechanisms. Most studies use 1.5–2.0 ATA for 40–60 sessions. Some researchers are exploring whether PTSD-specific protocols (targeting different session counts or combined with therapy) might be more effective.
Last updated: March 2026. Data sourced from manufacturer specifications, FDA databases, and published clinical research.
Use our filterable directory to find chambers that match your protocol requirements.